Comparative Pharmacology
Head-to-head clinical analysis: ESTARYLLA versus NORETHIN 1 35E 28.
Head-to-head clinical analysis: ESTARYLLA versus NORETHIN 1 35E 28.
ESTARYLLA vs NORETHIN 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Combination estrogen-progestin oral contraceptive. Ethinyl estradiol suppresses FSH and LH, preventing ovulation. Norethindrone alters cervical mucus and endometrial lining, inhibiting sperm penetration and implantation.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
One tablet orally once daily for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 35 mcg, followed by 7 inert tablets).
None Documented
None Documented
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Norethindrone: terminal elimination half-life approximately 8-11 hours. Ethinyl estradiol: terminal elimination half-life approximately 10-20 hours (mean ~13 hours). Clinical context: Steady-state achieved within 5 days; once-daily dosing maintains therapeutic levels.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Norethindrone is excreted primarily in urine as glucuronide and sulfate conjugates, with about 50-60% excreted renally; approximately 20-30% is excreted in feces via biliary elimination. Ethinyl estradiol is excreted in urine (40-60%) and feces (20-40%) after enterohepatic recirculation.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive